Revised the revenue for the fiscal year ending March 2026 to 449.0 billion yen (4.7% increase from previous forecast), operating income to 108.0 billion yen (10.2% increase), and net income attributable to owners of parent to 102.0 billion yen (10.9% increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4506-20260302-04.pdf","jir_short_summary":"Revised the revenue for the fiscal year ending March 2026 to 449.0 billion yen (4.7% increase from previous forecast), operating income to 108.0 billion yen (10.2% increase), and net income attributable to owners of parent to 102.0 billion yen (10.9% increase).","jir_summary":"### Details of Earnings Guidance Revision\nThe full-year consolidated earnings guidance for the fiscal year ending March 2026 has been revised, with revenue set at 449.0 billion yen (4.7% increase from previous forecast), operating income at 108.0 billion yen (10.2% increase), and net income attributable to owners of parent at 102.0 billion yen (10.9% increase). Core operating income has also been raised to 107.0 billion yen (10.3% increase).\n\n### Reasons and Background for the Revision\nThe increase in revenue reflects stronger-than-expected sales of the overactive bladder treatment \u2018Gemtesa\u2019 and other products in the North American segment, as well as the impact of yen depreciation. Core operating income was revised upward from the previous forecast due to higher gross profit gains, despite selling, general and administrative expenses and R&D expenses expected to be slightly below previous forecasts when excluding the yen depreciation effect. Consequently, operating income and net income were also revised upward.","jir_financial_highlights":"Revenue: 449,000 million yen (Year-over-Year unknown, 4.7% increase from previous forecast)\nCore Operating Income: 107,000 million yen (Year-over-Year unknown, 10.3% increase from previous forecast)\nOperating Income: 108,000 million yen (Year-over-Year unknown, 10.2% increase from previous forecast)\nNet Income Attributable to Owners of Parent: 102,000 million yen (Year-over-Year unknown, 10.9% increase from previous forecast)\nBasic Earnings Per Share: 256.74 yen (Year-over-Year unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #EarningsGuidanceRevision, #JapaneseStocks","jir_key_figures":"Revenue: 449,000 million yen (4.7% increase from previous forecast)\nOperating Income: 108,000 million yen (10.2% increase from previous forecast)\nNet Income Attributable to Owners of Parent: 102,000 million yen (10.9% increase from previous forecast)","jir_meta_title":"Sumitomo Pharma Revises Upward Earnings Guidance for Fiscal Year Ending March 2026: Revenue 449 Billion Yen, Operating Income 108 Billion Yen","jir_meta_description":"Sumitomo Pharma has revised upward its consolidated earnings guidance for the fiscal year ending March 2026 to revenue of 449.0 billion yen, operating income of 108.0 billion yen, and net income attributable to owners of parent of 102.0 billion yen. The main drivers are strong sales in the North American segment and the impact of yen depreciation.","jir_og_title":"Sumitomo Pharma Revises Upward Earnings Guidance for Fiscal Year Ending March 2026","jir_og_description":"Revised guidance to revenue of 449.0 billion yen and operating income of 108.0 billion yen, supported by strong sales in the North American segment.","jir_og_image_url":"\/assets\/og\/company-earnings_guidance.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-32743","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n